 |
85 Diseases |  |
38 Trials |
|
38 Trials |  |
1659 News |  |
| «12...234567891011121314» |
- | NovoLog (insulin aspart) / Novo Nordisk
New trial: Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=10, Completed, Sponsor: Aristotle University Of Thessaloniki
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone (clinicaltrials.gov) - Jun 7, 2017
P1, N=42, Recruiting, Sponsor: Adocia
- ||| Enrollment open: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Jun 2, 2017
P=N/A, N=150, Recruiting, Sponsor: Weill Cornell Medical College in Qatar
Not yet recruiting --> Recruiting
- Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) - Apr 19, 2017
P1, N=30, Recruiting, Sponsor: Wake Forest University Health Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Jul 2018
- | NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: Additional Insulin for Fat and Protein in Children With Diabetes Study (clinicaltrials.gov) - Apr 11, 2017
P4, N=40, Recruiting, Sponsor: Oxford University Hospitals NHS Trust
Trial primary completion date: Dec 2016 --> Jul 2018 Trial primary completion date: Feb 2017 --> Feb 2018
- | Tresiba (insulin degludec) / Novo Nordisk
Enrollment closed: HypoDeg: Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia (clinicaltrials.gov) - Mar 15, 2017
P4, N=149, Active, not recruiting, Sponsor: Nordsjaellands Hospital
Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Trial completion, Surgery: Linagliptin Inpatient Trial (clinicaltrials.gov) - Mar 10, 2017
P4, N=295, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Bydureon (exenatide XR once-weekly) / AstraZeneca, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy: Dexlar: Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (clinicaltrials.gov) - Mar 3, 2017
P4, N=0, Withdrawn, Sponsor: Weill Medical College of Cornell University
Recruiting --> Completed N=75 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jun 2018
- Apidra (insulin glulisine) / Sanofi
Enrollment open, Trial initiation date: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 1, 2017
P1, N=44, Recruiting, Sponsor: Sanofi
N=75 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Jun 2018 Suspended --> Recruiting | Initiation date: Sep 2016 --> Feb 2017
- Januvia (sitagliptin) / Merck (MSD)
Trial completion, Surgery: SITACABG NonDM: Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery (clinicaltrials.gov) - Feb 1, 2017
P4, N=68, Completed, Sponsor: Emory University
Suspended --> Recruiting | Initiation date: Sep 2016 --> Feb 2017 Recruiting --> Completed
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jan 30, 2017
P3, N=450, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Recruiting --> Active, not recruiting
- Victoza (liraglutide) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: PILGRIM: Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=150, Completed, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||||| NovoLog Mix 70/30 (insulin aspart protamine 70%/insulin aspart 30%) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: ACTION: Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 10, 2017
P3, N=230, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed No longer recruiting --> Completed
- ||| NovoLog Mix 70/30 (insulin aspart protamine 70%/insulin aspart 30%) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Reliability of Dosing With NovoLog (clinicaltrials.gov) - Jan 5, 2017
P1, N=60, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents (clinicaltrials.gov) - Dec 21, 2016
P3, N=299, Completed, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed No longer recruiting --> Completed
- || New P3 trial: The SUGAR-DIP trial: Oral medication versus insulin for diabetes in pregnancy De SUGAR-DIP trial: Orale medicatie versus insuline voor zwangerschapsdiabetes (EUDRACT) - Dec 21, 2016
P3, N=810, Ongoing, Sponsor: University Medical Center Utrecht
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: onset (clinicaltrials.gov) - Nov 28, 2016
P3, N=1130, Active, not recruiting, Sponsor: Novo Nordisk A/S
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- Apidra (insulin glulisine) / Sanofi
Trial suspension, Trial primary completion date: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Nov 3, 2016
P1, N=44, Suspended, Sponsor: Sanofi
Recruiting --> Active, not recruiting Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> May 2017
- | NovoLog (insulin aspart) / Novo Nordisk
Phase classification: Surveillance Study of NovoRapid (clinicaltrials.gov) - Oct 28, 2016
P4, N=1239, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> May 2017 Phase classification: P=N/A --> P4
- Apidra (insulin glulisine) / Sanofi
Enrollment open: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 21, 2016
P1, N=44, Recruiting, Sponsor: Sanofi
Phase classification: P=N/A --> P4 Not yet recruiting --> Recruiting
- Lantus (insulin glargine) / Sanofi, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes (clinicaltrials.gov) - Oct 21, 2016
P4, N=250, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Oct 2017
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Additional Insulin for Fat and Protein in Children With Diabetes Study (clinicaltrials.gov) - Oct 13, 2016
P4, N=40, Recruiting, Sponsor: Oxford University Hospitals NHS Trust
Trial primary completion date: Oct 2016 --> Oct 2017 Not yet recruiting --> Recruiting
- | Apidra (insulin glulisine) / Sanofi
New P1 trial: A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 22, 2016
P1, N=44, Not yet recruiting, Sponsor: Sanofi
- ||| New trial: HbA1c Variability in Type II Diabetes (clinicaltrials.gov) - Aug 25, 2016
P=N/A, N=150, Not yet recruiting, Sponsor: Weill Cornell Medical College in Qatar
- Trial completion, Phase classification, Enrollment change, Trial primary completion date: Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs (clinicaltrials.gov) - Aug 25, 2016
P1, N=36, Completed, Sponsor: Yale University
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed | Phase classification: PN/A --> P1 | N=75 --> 36 | Trial primary completion date: Apr 2010 --> Sep 2011
- NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: Clinical Effects of Pulsatile Insulin Delivery on Cognitive Function- Phase 1 (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=75, Terminated, Sponsor: Florida Atlantic University
Enrolling by invitation --> Completed | Phase classification: PN/A --> P1 | N=75 --> 36 | Trial primary completion date: Apr 2010 --> Sep 2011 Trial primary completion date: Jun 2010 --> Aug 2009
- NovoLog (insulin aspart) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment change, Trial withdrawal: Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes (clinicaltrials.gov) - Aug 11, 2016
P3, N=0, Withdrawn, Sponsor: Florida Atlantic University
Trial primary completion date: Jun 2010 --> Aug 2009 N=400 --> 0 | Terminated --> Withdrawn
- NovoLog (insulin aspart) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment change, Trial primary completion date: Effects of Pulsatile Intravenous Insulin Therapy on Metabolic Integrity in Patients With Diabetes Mellitus (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=152, Terminated, Sponsor: Florida Atlantic University
N=400 --> 0 | Terminated --> Withdrawn N=750 --> 152 | Trial primary completion date: Nov 2011 --> Aug 2009
- | NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial primary completion date: Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=150, Terminated, Sponsor: Florida Atlantic University
N=750 --> 152 | Trial primary completion date: Nov 2011 --> Aug 2009 N=500 --> 150 | Trial primary completion date: Dec 2011 --> Aug 2009
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial withdrawal: Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=0, Withdrawn, Sponsor: Florida Atlantic University
N=500 --> 150 | Trial primary completion date: Dec 2011 --> Aug 2009 N=400 --> 0 | Terminated --> Withdrawn
- | NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial primary completion date: Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=152, Terminated, Sponsor: Florida Atlantic University
N=400 --> 0 | Terminated --> Withdrawn N=500 --> 152 | Trial primary completion date: May 2011 --> Aug 2009
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial primary completion date, HEOR: Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=152, Terminated, Sponsor: Florida Atlantic University
N=500 --> 152 | Trial primary completion date: May 2011 --> Aug 2009 N=500 --> 152 | Trial primary completion date: Jan 2010 --> Aug 2009
- NovoLog (insulin aspart) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment change, Trial withdrawal, Trial primary completion date: Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness (clinicaltrials.gov) - Aug 11, 2016
P2/3, N=0, Withdrawn, Sponsor: Florida Atlantic University
N=500 --> 152 | Trial primary completion date: Jan 2010 --> Aug 2009 N=400 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Jan 2012 --> Aug 2009
- NovoLog (insulin aspart) / Novo Nordisk, Humulin R (recombinant human insulin) / Alzheimer's Disease Cooperative Study, Eli Lilly
Enrollment change: Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics (clinicaltrials.gov) - Aug 10, 2016
P2/3, N=152, Terminated, Sponsor: Florida Atlantic University
N=400 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Jan 2012 --> Aug 2009 N=300 --> 152
- NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial primary completion date: Effect of Pulsatile IV Insulin on Circulating Risk Markers of Vascular and Metabolic Complications in Pts With Diabetes (clinicaltrials.gov) - Aug 10, 2016
P2/3, N=105, Terminated, Sponsor: Florida Atlantic University
N=300 --> 152 N=500 --> 105 | Trial primary completion date: Jun 2010 --> Aug 2009
- Victoza (liraglutide) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: PILGRIM: Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus (clinicaltrials.gov) - Aug 9, 2016
P=N/A, N=150, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
N=500 --> 105 | Trial primary completion date: Jun 2010 --> Aug 2009 N=315 --> 150
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change, Trial withdrawal: BEER: How to be Safe With Alcoholic Drinks in Diabetes (clinicaltrials.gov) - Aug 8, 2016
P=N/A, N=0, Withdrawn, Sponsor: Kinderkrankenhaus auf der Bult
N=315 --> 150 N=24 --> 0 | Recruiting --> Withdrawn
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Aug 5, 2016
P3, N=450, Recruiting, Sponsor: Novo Nordisk A/S
N=24 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Enrollment open: Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps. (clinicaltrials.gov) - Jul 29, 2016
P4, N=70, Recruiting, Sponsor: Medical University of Warsaw
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Jul 27, 2016
P3, N=833, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Mar 2018
- Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: BEER: How to be Safe With Alcoholic Drinks in Diabetes (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=24, Recruiting, Sponsor: Kinderkrankenhaus auf der Bult
Trial primary completion date: Dec 2017 --> Mar 2018 Trial primary completion date: Apr 2016 --> Jul 2016
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jul 7, 2016
P3, N=450, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Januvia (sitagliptin) / Merck (MSD)
Enrollment open, Surgery: Sitagliptin in Non-Diabetic Patients Undergoing General Surgery (clinicaltrials.gov) - Jun 29, 2016
P4, N=80, Recruiting, Sponsor: Emory University
Trial primary completion date: Apr 2016 --> Jul 2016 Not yet recruiting --> Recruiting
- | Bydureon (exenatide XR once-weekly) / AstraZeneca, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
New P4 trial, Combination therapy: Dexlar: Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes (clinicaltrials.gov) - Jun 23, 2016
P4, N=75, Recruiting, Sponsor: Weill Medical College of Cornell University
- | Levemir (insulin detemir rDNA origin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) - May 19, 2016
P2/3, N=80, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: onset (clinicaltrials.gov) - May 12, 2016
P3, N=1130, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Insulatard (isophane insulin) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Enrollment change, Trial primary completion date: TIP: Treatment of Impaired Glucose Tolerance in Pregnancy (clinicaltrials.gov) - May 12, 2016
P=N/A, N=72, Completed, Sponsor: University Hospital Orebro
Not yet recruiting --> Recruiting Recruiting --> Completed | N=500 --> 72 | Trial primary completion date: Sep 2011 --> Jun 2012
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: onset (clinicaltrials.gov) - May 5, 2016
P3, N=833, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=500 --> 72 | Trial primary completion date: Sep 2011 --> Jun 2012 Not yet recruiting --> Recruiting
- | Januvia (sitagliptin) / Merck (MSD)
New P4 trial, Surgery: Sitagliptin in Non-Diabetic Patients Undergoing General Surgery (clinicaltrials.gov) - Apr 18, 2016
P4, N=80, Not yet recruiting, Sponsor: Emory University
- |||| Januvia (sitagliptin) / Merck (MSD)
Trial completion, Surgery: Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes (clinicaltrials.gov) - Apr 14, 2016
P4, N=292, Completed, Sponsor: Emory University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed